机译:临床抑制剂抑制HIV-1蛋白酶的天然变异体和多药耐药突变体前体的自加工
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Esethesda, MD 20892;
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Esethesda, MD 20892;
Department of Biology, Molecular Basis of Disease Program, Georgia State University, Atlanta, GA 30303;
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services, Esethesda, MD 20892;
calorimetry; drug resistance; precursor processing; inhibitor binding; aspartic protease;
机译:GRL-079是一种新型HIV-1蛋白酶抑制剂,对多药抗性HIV-1变体极其有效,并且具有抗抗性变体的出现的高遗传障碍
机译:GRL-079是一种新型HIV-1蛋白酶抑制剂,对多药抗性HIV-1变体极其有效,并且具有抗抗性变体的出现的高遗传障碍
机译:临床抑制剂与合理选择的多药抗性HIV-1蛋白酶的模型前体的结合比对释放的成熟酶的结合明显弱。
机译:HIV-1蛋白酶抑制剂复合物中耐药突变的分子建模和结合能量计算
机译:基于结构的抗多药HIV-1蛋白酶变体有效抑制剂的设计。
机译:临床抑制剂抑制HIV-1蛋白酶的天然变异体和多药耐药突变体前体的自加工
机译:临床抑制剂抑制HIV-1蛋白酶的天然变异体和多药耐药突变体前体的自加工